KH Elisabethinen Linz Report issue

Academic/Hospital Phase 2 Phase 3
Founded: Linz Austria (1690)

Organization Overview

First Clinical Trial
2007
NCT00890422
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Elisabethinen Hospital | Elisabethinen hospital Linz GmbH | Prim. Priv. Doz. Dr. Daniel Cejka

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Calcinosis (Phase 2)

Encephalitis (Phase 2)

Encephalitis, Tick-Borne (Phase 2)

Kidney Failure, Chronic (Phase 2)

Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 7
  • # of Trial APIs: 8